Private Label Contract Manufacturing was Natural Alternatives International’s largest segment in fiscal 2026, bringing in $134.62M of $142.52M (94%).
| Segment | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Label Contract Manufacturing | $145.29M | $105.36M | $121.78M | $134.62M | ||||||||||||
| Patent & Trademark Licensing | $8.72M | $8.44M | $8.08M | $7.90M | ||||||||||||
| Branded Products | — | — | — | — | ||||||||||||
| Total | $154.02M | $113.80M | $129.86M | $142.52M |
Natural Alternatives International brought in $142.52M from its two segments in fiscal 2026, the year ended June 30, 2026. That was up 9.7% from $129.86M in fiscal 2025. Private Label Contract Manufacturing was the largest at $134.62M (94.5%), ahead of Patent & Trademark Licensing at $7.90M (5.5%).
Compared with fiscal 2025, Private Label Contract Manufacturing grew 10.5% to $134.62M, while Patent & Trademark Licensing fell 2.2% to $7.90M. From fiscal 2023 to 2026, combined revenue from these segments fell from $154.02M to $142.52M, a compound annual decline of 2.6%. Private Label Contract Manufacturing's share held steady at about 94.5%.
United States was Natural Alternatives International’s largest region in fiscal 2026, bringing in $93.32M of $142.52M (65%).
| Geography | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $109.28M | $73.51M | $79.13M | $93.32M | ||||||||||||
| Non-Us | $44.74M | $40.28M | $50.73M | $49.19M | ||||||||||||
| Markets Outside The United States | — | — | — | — | ||||||||||||
| Total | $154.02M | $113.80M | $129.86M | $142.52M |
Natural Alternatives International brought in $142.52M from its two regions in fiscal 2026, the year ended June 30, 2026. That was up 9.7% from $129.86M in fiscal 2025. United States was the largest at $93.32M (65.5%), ahead of Non-Us at $49.19M (34.5%).
Compared with fiscal 2025, United States grew 17.9% to $93.32M, while Non-Us fell 3.0% to $49.19M. From fiscal 2023 to 2026, combined revenue from these regions fell from $154.02M to $142.52M, a compound annual decline of 2.6%. United States' share of the total fell from 71.0% to 65.5%.
Customer 1 was Natural Alternatives International’s largest revenue line in fiscal 2026, bringing in $39.80M of $73.52M (54%).
| Customer | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Customer 1 | — | — | $39.80M |
| Operating Segments | $105.36M | $121.78M | — |
| Customer 2 | — | — | $33.72M |
| Total | $105.36M | $121.78M | $73.52M |
Natural Alternatives International brought in $73.52M from its two revenue lines in fiscal 2026, the year ended June 30, 2026. That is less than the $142.52M it reports by segment, so these revenue lines do not cover all of its revenue. Customer 1 was the largest at $39.80M (54.1%), ahead of Customer 2 at $33.72M (45.9%).
Natural Alternatives International began breaking out Customer 1 in fiscal 2026 and Customer 2 in fiscal 2026. Natural Alternatives International stopped reporting Operating Segments as a separate revenue line after fiscal 2025, when it brought in $121.78M.
Natural Alternatives International (NAII) reports its revenue by segment, by geography and by customer. In fiscal 2026, Private Label Contract Manufacturing was its largest segment, bringing in $134.62M (94.5% of the total), followed by Patent & Trademark Licensing at $7.90M (5.5%).
Private Label Contract Manufacturing was Natural Alternatives International's largest segment in fiscal 2026, bringing in $134.62M, or 94.5% of the $142.52M total across its two segments.
United States was Natural Alternatives International's largest region in fiscal 2026, bringing in $93.32M, or 65.5% of the $142.52M total across its two regions.
Customer 1 was Natural Alternatives International's largest revenue line in fiscal 2026, bringing in $39.80M, or 54.1% of the $73.52M total across its two revenue lines.
Private Label Contract Manufacturing grew faster than Patent & Trademark Licensing in fiscal 2026, up 10.5% from $121.78M to $134.62M. Patent & Trademark Licensing fell 2.2% to $7.90M.
Every figure comes from Natural Alternatives International's annual financial filings, as reported. Each line keeps the name Natural Alternatives International gives it, and years follow its fiscal calendar.
Natural Alternatives International's revenue by segment goes back to fiscal 2011, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.